No Data
No Data
Third Harmonic Bio (NASDAQ:THRD) Is In A Strong Position To Grow Its Business
Third Harmonic Bio to Participate in Upcoming Investor Conferences
Third Harmonic Shares Are Trading Higher on Continued Strength After the Company Reported Q2 Financial Results Yesterday. Also, Morgan Stanley Upgraded the Stock From Equal-Weight to Overweight and Raised Its Price Target From $12 to $20.
Express News | Third Harmonic Bio Inc : Morgan Stanley Raises to Overweight
Express News | Third Harmonic Bio Inc : Morgan Stanley Raises Target Price to $20.00 From $12.00
Buy Rating Affirmed for Third Harmonic Bio Amidst Promising Clinical Developments and Market Prospects